6978 — Immunotech Biopharm Share Price
Last trade - 00:00- HK$1.70bn
- HK$1.65bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.07 | ||
| Price to Tang. Book | 11.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.78% | ||
| Return on Equity | -98.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.
Directors
- Zheng Tan CHM (43)
- Yu Wang CEO (53)
- Ning Yang CFO (39)
- Jian Zhang SVP (50)
- Hyun-soo Kim CTO (59)
- Yu Zhang CSO (57)
- Hyun Chul Jung EDR (58)
- Yuan Lu NED (31)
- Xiaobing Si NED (40)
- Ran Tao NED (55)
- Chi Kit Ng NID (47)
- Sujiu Peng NID (41)
- Yingdian Wang NID (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 11th, 2018
- Public Since
- July 10th, 2020
- No. of Employees
- 210
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 514,584,000
- Address
- 8th Floor, Building 1, Beijing
- Web
- http://www.eaal.net/
- Phone
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 6978
Similar to 6978
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:11 UTC, shares in Immunotech Biopharm are trading at HK$3.31. This share price information is delayed by 15 minutes.
Shares in Immunotech Biopharm last closed at HK$3.31 and the price had moved by -11.02% over the past 365 days. In terms of relative price strength the Immunotech Biopharm share price has underperformed the FTSE Developed Asia Pacific Index by -10.94% over the past year.
The overall consensus recommendation for Immunotech Biopharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Immunotech Biopharm does not currently pay a dividend.
Immunotech Biopharm does not currently pay a dividend.
Immunotech Biopharm does not currently pay a dividend.
To buy shares in Immunotech Biopharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$3.31, shares in Immunotech Biopharm had a market capitalisation of HK$1.70bn.
Here are the trading details for Immunotech Biopharm:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6978
Based on an overall assessment of its quality, value and momentum Immunotech Biopharm is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunotech Biopharm. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -27.22%.
As of the last closing price of HK$3.31, shares in Immunotech Biopharm were trading -16.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Immunotech Biopharm PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$3.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Immunotech Biopharm's management team is headed by:
- Zheng Tan - CHM
- Yu Wang - CEO
- Ning Yang - CFO
- Jian Zhang - SVP
- Hyun-soo Kim - CTO
- Yu Zhang - CSO
- Hyun Chul Jung - EDR
- Yuan Lu - NED
- Xiaobing Si - NED
- Ran Tao - NED
- Chi Kit Ng - NID
- Sujiu Peng - NID
- Yingdian Wang - NID